keyword
MENU ▼
Read by QxMD icon Read
search

Oncology Updates

keyword
https://www.readbyqxmd.com/read/28740405/novel-agents-for-the-treatment-of-childhood-leukemia-an-update
#1
REVIEW
Ertugrul Eryılmaz, Cengiz Canpolat
Achieving lower morbidity and higher survival rates in the treatment of childhood leukemia has been a paradigm of success in modern oncology. However, serious long-term health complications occur in very large populations of childhood leukemia survivors, in the case of both acute lymphoid leukemia and acute myeloid leukemia (AML). Additionally, 15% of acute lymphoid leukemia patients have treatment failures, and rates are even higher in childhood AML. In the last few decades, as a result of well-tested experiments that statistically analyzed treatment cohorts, new agents have emerged as alternatives or supplements to established treatments, in which high survival and/or less morbidity were observed...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28739117/update-on-fertility-preservation-from-the-barcelona-international-society-for-fertility-preservation-eshre-asrm-2015-expert-meeting-indications-results-and-future-perspectives
#2
Francisca Martinez
STUDY QUESTION: What progress has been made in fertility preservation (FP) over the last decade? SUMMARY ANSWER: FP techniques have been widely adopted over the last decade and therefore the establishment of international registries on their short- and long-term outcomes is strongly recommended. WHAT IS KNOWN ALREADY: FP is a fundamental issue for both males and females whose future fertility may be compromised. Reproductive capacity may be seriously affected by age, different medical conditions and also by treatments, especially those with gonadal toxicity...
July 20, 2017: Fertility and Sterility
https://www.readbyqxmd.com/read/28736625/entering-the-molecular-era-of-gastrointestinal-oncology-current-updates-and-challenges
#3
EDITORIAL
Andrea Wang-Gillam, Kian-Huat Lim
No abstract text is available yet for this article.
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28735365/an-update-on-the-use-of-immunotherapy-in-the-treatment-of-lymphoma
#4
REVIEW
Thomas U Marron, Matko Kalac, Joshua Brody
PURPOSE OF REVIEW: Throughout the field of oncology, immunotherapy is moving further towards the first-line setting, and there is encouraging data for the use of these novel therapies in the management of lymphomas, utilizing treatments approved for both solid and hematologic malignancies. Herein, we review promising advances in this rapidly moving field from the past year. RECENT FINDINGS: In the last year, we have seen promising clinical data on engineered antibody therapies for the treatment of lymphomas, as well as further optimization of engineered antibody fragments fused onto linkers or chimeric T cell receptors, both of the modalities capable of transforming non-specific T cells into tumor-specific, serial killer cells...
July 22, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28729026/micrornas-in-oncogenesis-and-tumor-suppression
#5
Simona Barbato, Giancarlo Solaini, Muller Fabbri
MicroRNAs (MiRNAs) have emerged in the last 15 years as central players in the biology of cancer. Increasing lines of evidence have supported their regulatory role in the expression of both oncogenes and tumor-suppressor genes, progressively clarifying which genes are modulated by specific MiRNAs dysregulated in cancer. Intriguingly, a "target-specific" understanding of MiRNA function in oncology has been replaced by a more "pathway-specific" vision of their involvement in cancer biology. This work provides a state-of-the-art knowledge of the role of MiRNAs in the most frequently altered signaling pathways in cancer cells and provides an updated overview on some of the most relevant findings trying to decode the complex molecular mechanisms of cancer...
2017: International Review of Cell and Molecular Biology
https://www.readbyqxmd.com/read/28725926/the-intensive-care-medicine-research-agenda-on-critically-ill-oncology-and-hematology-patients
#6
REVIEW
Elie Azoulay, Peter Schellongowski, Michael Darmon, Philippe R Bauer, Dominique Benoit, Pieter Depuydt, Jigeeshu V Divatia, Virginie Lemiale, Maarten van Vliet, Anne-Pascale Meert, Djamel Mokart, Stephen M Pastores, Anders Perner, Frédéric Pène, Peter Pickkers, Kathryn A Puxty, Francois Vincent, Jorge Salluh, Ayman O Soubani, Massimo Antonelli, Thomas Staudinger, Michael von Bergwelt-Baildon, Marcio Soares
Over the coming years, accelerating progress against cancer will be associated with an increased number of patients who require life-sustaining therapies for infectious or toxic chemotherapy-related events. Major changes include increased number of cancer patients admitted to the ICU with full-code status or for time-limited trials, increased survival and quality of life in ICU survivors, changing prognostic factors, early ICU admission for optimal monitoring, and use of noninvasive diagnostic and therapeutic strategies...
July 19, 2017: Intensive Care Medicine
https://www.readbyqxmd.com/read/28725278/asco-2016-update-colorectal-liver-metastases
#7
REVIEW
Klaus Kaczirek
This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a large registry study, small, upfront resectable, solitary CLM should be resected using a parenchymal sparing technique. A prospective noninterventional study suggested that chemotherapy plus the anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is effective and well tolerated in patients with borderline resectable CLM...
2017: Memo
https://www.readbyqxmd.com/read/28713700/transoral-endoscopic-thyroidectomy-using-vestibular-approach-updates-and-evidences
#8
REVIEW
Angkoon Anuwong, Hoon Yub Kim, Gianlorenzo Dionigi
Recently, natural orifice transluminal endoscopic surgery (NOTES) has been applied in thyroid surgery with transoral access. The benefit of transoral endoscopic thyroidectomy is the potential for scar-free surgery. However, there are many concerns over some aspects, such as infection, recurrent laryngeal nerve injury, and oncological outcome. In this paper, we have reviewed the development history and the current clinical evidence of this innovative surgery. We conclude that the transoral endoscopic thyroidectomy vestibular approach (TOETVA) is feasible and can be considered no longer an experimental operation...
June 2017: Gland Surgery
https://www.readbyqxmd.com/read/28712009/analysis-of-molecular-subtypes-for-the-increased-her2-equivocal-cases-caused-by-application-of-the-updated-2013-asco-cap-her2-testing-guidelines-in-breast-cancer
#9
Lei Guo, Pei Yuan, Jing Zhang, Yun Ling, Wenbin Li, Bohui Zhao, Jianming Ying, Lixue Xuan
PURPOSE: Accurate testing of the status of human epidermal growth factor receptor type 2 (HER2) is a prerequisite for HER2-directed therapy. The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) published joint guideline recommendations for HER2 testing in breast cancer in 2007 and it was updated in 2013. We compared the HER2 gene amplification status based on these two guidelines and analyzed the molecular characteristics of the equivocal cases...
July 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28700368/regional-anesthesia-and-analgesia-in-cancer-care-is-it-time-to-break-the-bad-news
#10
Mir W Sekandarzad, André A J van Zundert, Chris W Doornebal, Markus W Hollmann
PURPOSE OF REVIEW: There is ongoing controversy regarding the tumor-protective effects of regional anesthesia in patients undergoing cancer surgery. Evidence of up-to-date systematic reviews will be presented alongside recent updates on the effects of opioids and local anesthetics. RECENT FINDINGS: In recent years, the literature regarding the effects of regional anesthesia techniques on cancer recurrence has raised many unanswered questions. Ongoing randomized controlled trials may not be able to shed light on the controversial discussion regarding the tumor protective effects of regional anesthesia because the expected effect size and event rate in those studies may be overstated...
July 11, 2017: Current Opinion in Anaesthesiology
https://www.readbyqxmd.com/read/28699165/ultrasound-guided-core-needle-biopsy-in-salivary-glands-a-meta-analysis
#11
REVIEW
Hee Joon Kim, Jong Seung Kim
OBJECTIVES/HYPOTHESIS: Core needle biopsy is an effective diagnostic tool widely used in many oncological diagnostic approaches. It provides an adequate tissue sample for histological evaluation of architecture, which allows tumor grading and classification of malignant and benign tumors. This study aimed to provide an updated meta-analysis and systematic review of core needle biopsy in the salivary glands. STUDY DESIGN: A literature search using PubMed, Embase, and the Cochrane Library through December 2016...
July 12, 2017: Laryngoscope
https://www.readbyqxmd.com/read/28696818/use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with-early-stage-invasive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-focused-update-guideline-summary
#12
https://www.readbyqxmd.com/read/28692382/use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with-early-stage-invasive-breast-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-focused-update
#13
Ian Krop, Nofisat Ismaila, Fabrice Andre, Robert C Bast, William Barlow, Deborah E Collyar, M Elizabeth Hammond, Nicole M Kuderer, Minetta C Liu, Robert G Mennel, Catherine Van Poznak, Antonio C Wolff, Vered Stearns
Purpose This focused update addresses the use of MammaPrint (Agendia, Irvine, CA) to guide decisions on the use of adjuvant systemic therapy. Methods ASCO uses a signals approach to facilitate guideline updates. For this focused update, the publication of the phase III randomized MINDACT (Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy) study to evaluate the MammaPrint assay in 6,693 women with early-stage breast cancer provided a signal. An expert panel reviewed the results of the MINDACT study along with other published literature on the MammaPrint assay to assess for evidence of clinical utility...
July 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28690767/endoscopic-ultrasound-in-oncology-an-update-of-clinical-applications-in-the-gastrointestinal-tract
#14
REVIEW
Manuel Valero, Carlos Robles-Medranda
An accurate staging is necessary to select the best treatment and evaluate prognosis in oncology. Staging usually begins with noninvasive imaging such as computed tomography, magnetic resonance imaging or positron emission tomography. In the absence of distant metastases, endoscopic ultrasound plays an important role in the diagnosis and staging of gastrointestinal tumors, being the most accurate modality for local-regional staging. Its use for tumor and nodal involvement in pre-surgical evaluation has proven to reduce unnecessary surgeries...
June 16, 2017: World Journal of Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/28689670/espen-expert-group-recommendations-for-action-against-cancer-related-malnutrition
#15
REVIEW
J Arends, V Baracos, H Bertz, F Bozzetti, P C Calder, N E P Deutz, N Erickson, A Laviano, M P Lisanti, D N Lobo, D C McMillan, M Muscaritoli, J Ockenga, M Pirlich, F Strasser, M de van der Schueren, A Van Gossum, P Vaupel, A Weimann
Patients with cancer are at particularly high risk for malnutrition because both the disease and its treatments threaten their nutritional status. Yet cancer-related nutritional risk is sometimes overlooked or under-treated by clinicians, patients, and their families. The European Society for Clinical Nutrition and Metabolism (ESPEN) recently published evidence-based guidelines for nutritional care in patients with cancer. In further support of these guidelines, an ESPEN oncology expert group met for a Cancer and Nutrition Workshop in Berlin on October 24 and 25, 2016...
June 23, 2017: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/28687576/nccn-guidelines-insights-antiemesis-version-2-2017
#16
Michael J Berger, David S Ettinger, Jonathan Aston, Sally Barbour, Jason Bergsbaken, Philip J Bierman, Debra Brandt, Dawn E Dolan, Georgiana Ellis, Eun Jeong Kim, Steve Kirkegaard, Dwight D Kloth, Ruth Lagman, Dean Lim, Charles Loprinzi, Cynthia X Ma, Victoria Maurer, Laura Boehnke Michaud, Lisle M Nabell, Kim Noonan, Eric Roeland, Hope S Rugo, Lee S Schwartzberg, Bridget Scullion, John Timoney, Barbara Todaro, Susan G Urba, Dorothy A Shead, Miranda Hughes
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis address all aspects of management for chemotherapy-induced nausea and vomiting. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Antiemesis, specifically those regarding carboplatin, granisetron, and olanzapine.
July 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28685821/pd-1-pd-l1-inhibitors-in-haematological-malignancies-update-2017
#17
REVIEW
Tomas Jelinek, Jana Mihalyova, Michal Kascak, Juraj Duras, Roman Hajek
The introduction of PD-1/PD-L1 pathway inhibitors is an important landmark in solid oncology with unprecedented practice-changing activity in various types of solid tumours. Amongst haematological malignancies, PD-1/PD-L1 inhibitors have been successful, so far, only in the treatment of classical Hodgkin lymphoma, which typically exhibits an over-expression of PD-1 ligands (PD-L1, PD-L2) due to alterations in chromosome 9p24.1. Such positive outcomes led to the FDA approval of nivolumab use in relapsed Hodgkin lymphoma in 2016 as the first haematological indication...
July 6, 2017: Immunology
https://www.readbyqxmd.com/read/28666551/european-organization-for-research-and-treatment-of-cancer-eortc-recommendations-for-planning-and-delivery-of-high-dose-high-precision-radiotherapy-for-lung-cancer
#18
Dirk De Ruysscher, Corinne Faivre-Finn, Ditte Moeller, Ursula Nestle, Coen W Hurkmans, Cécile Le Péchoux, José Belderbos, Matthias Guckenberger, Suresh Senan
PURPOSE: To update literature-based recommendations for techniques used in high-precision thoracic radiotherapy for lung cancer, in both routine practice and clinical trials. METHODS: A literature search was performed to identify published articles that were considered clinically relevant and practical to use. Recommendations were categorised under the following headings: patient positioning and immobilisation, Tumour and nodal changes, CT and FDG-PET imaging, target volumes definition, radiotherapy treatment planning and treatment delivery...
June 27, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28644913/supplement-2-for-the-2004-update-of-the-aapm-task-group-no-43-report-joint-recommendations-by-the-aapm-and-gec-estro
#19
Mark J Rivard, Facundo Ballester, Wayne M Butler, Larry A DeWerd, Geoffrey S Ibbott, Ali S Meigooni, Christopher S Melhus, Michael G Mitch, Ravinder Nath, Panagiotis Papagiannis
Since publication of the 2004 update to the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report (TG-43U1) and its 2007 supplement (TG-43U1S1), several new low-energy photon-emitting brachytherapy sources have become available. Many of these sources have satisfied the AAPM prerequisites for routine clinical purposes and are posted on the Brachytherapy Seed Registry managed jointly by the AAPM and the Imaging and Radiation Oncology Core Houston Quality Assurance Center (IROC Houston)...
June 23, 2017: Medical Physics
https://www.readbyqxmd.com/read/28640707/response-assessment-in-neuro-oncology-clinical-trials
#20
Patrick Y Wen, Susan M Chang, Martin J Van den Bent, Michael A Vogelbaum, David R Macdonald, Eudocia Q Lee
Development of novel therapies for CNS tumors requires reliable assessment of response and progression. This requirement has been particularly challenging in neuro-oncology for which contrast enhancement serves as an imperfect surrogate for tumor volume and is influenced by agents that affect vascular permeability, such as antiangiogenic therapies. In addition, most tumors have a nonenhancing component that can be difficult to accurately quantify. To improve the response assessment in neuro-oncology and to standardize the criteria that are used for different CNS tumors, the Response Assessment in Neuro-Oncology (RANO) working group was established...
July 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
25528
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"